MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Cash received forsale of business, net$363,222K Proceeds from sales andmaturities of investments$15,000K Net cash provided byinvesting activities$191,090K Effect of foreignexchange rate...$115K Canceled cashflow$187,132K Net increase(decrease) in cash, cash...$144,568K Canceled cashflow$46,637K Purchases of short-termmarketable debt securities$127,208K Purchases of long-termmarketable debt securities$58,517K Purchases of marketableequity securities$837K Purchases of property andequipment$570K Net income (loss)$127,068K Deferred tax asset,non-current$38,359K Stock-based compensationexpense$8,824K Unrealized loss on equityinvestments-$3,494K Inventory-$1,935K Depreciation andamortization$1,408K Non-cash lease expense$1,355K Provision for excess andobsolete inventory$696K Other non-cash items$67K Other liabilities$1K Proceeds from exercise ofstock options$78K Net cash used inoperating activities-$46,597K Net cash used infinancing activities-$40K Canceled cashflow$183,207K Canceled cashflow$78K Gain on sale ofbusiness$172,289K Payments for taxesrelated to net share...$118K Deferred revenue-$29,934K Accrued liabilities-$20,785K Accounts receivable, net$1,858K Prepaid expenses andother assets$1,592K Operating leaseliabilities-$1,490K Accounts payable-$1,224K Accretion of discount onshort-term investments,...$632K
Cash Flow

STANDARD BIOTOOLS INC. (LAB)

STANDARD BIOTOOLS INC. (LAB)

source: myfinsight.com